EssilorLuxottica Announces Agreement to Acquire Espansione Group
EssilorLuxottica’s 2024 shopping spree continues with a move into dry eye and retinal disease treatment. 2024 may be drawing to…
EyePoint Doses First Patient in Second DURAVYU™ Phase 3 Trial for Wet AMD
The firm is gathering safety and efficacy evidence for its sustained delivery, selective tyrosine kinase inhibitor nAMD treatment. EyePoint Pharmaceuticals…
latest posts